The future of early endpoints for neoadjuvant therapy
Cancer Cell · 2026-11
DOI: 10.1016/j.ccell.2026.10.010 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Cell, 2026-11. Verfasst von Christina Yau und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgery, University of California San Francisco, San Francisco, CA, USA. Die Arbeit nennt 10 Literaturangaben.
Abstract (Originalsprache)
Early endpoints as surrogates for long-term outcomes are essential for treatment efficacy evaluation. In this issue of Cancer Cell, Conforti et al. report that CPS + EG and Neo-Bioscore scores predict long-term outcomes at the patient level but not at the trial level, highlighting the need for better early endpoints that reliably capture efficacy across trials.
Autor:innen und Institutionen
- Department of Surgery, University of California San Francisco, San Francisco, CA, USA.
- Department of Surgery, University of California San Francisco, San Francisco, CA, USA. Electronic address: laura.esserman@ucsf.edu.
Zitieren
APA
Yau, C., & Esserman, L. J. (2026). The future of early endpoints for neoadjuvant therapy. Cancer Cell. https://doi.org/10.1016/j.ccell.2026.10.010
Vancouver
Yau C, Esserman LJ. The future of early endpoints for neoadjuvant therapy. Cancer Cell. 2026. doi:10.1016/j.ccell.2026.10.010
BibTeX
@article{Yau2026,
author = {Yau, Christina and Esserman, Laura J},
title = {The future of early endpoints for neoadjuvant therapy},
journal = {Cancer Cell},
year = {2026},
doi = {10.1016/j.ccell.2026.10.010}
}
EUVIMED